Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies

Journal of Clinical Oncology

Volumn 23, Issue 17, 2005, Pages 3971-3993

  Bhalla, Kapil N ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; 4 N ACETYLDINALINE; 5 AZA 2' DEOXYCYTIDINE; 5 AZACITIDINE; APICIDIN; AZACITIDINE; BORTEZOMIB; CYCLOHEXIMIDE; DEOXYCYTIDINE; FR 901228; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; UNCLASSIFIED DRUG; VORINOSTAT; ZEBULARINE; HISTONE DEACETYLASE; METHYLTRANSFERASE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; BONE MARROW SUPPRESSION; CHROMATIN; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTINUOUS INFUSION; DNA METHYLATION; DRUG MECHANISM; EPIGENETICS; FATIGUE; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENETIC REGULATION; GENETIC TRANSCRIPTION; HEART ARRHYTHMIA; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOALBUMINEMIA; NAUSEA; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC EPIGENESIS; GENETICS; METABOLISM; NEOPLASM; PROMOTER REGION;

CHROMATIN; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENE THERAPY; HISTONE DEACETYLASES; HUMANS; METHYLTRANSFERASES; NEOPLASMS; PROMOTER REGIONS (GENETICS);

EID: 21244467166     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.16.600     Document Type: Review

References (303)

1. Bird A: DNA methylation patterns and epigenetic memory. Genes Dev 16:6-21, 2002
2. Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415-428, 2002
3. Baylin SB, Herman JG: DNA hypermethylation in tumorigenesis: Epigenetics joins genetics. Trends Genet 16:168-174, 2000
4. Feinberg AP, Tycko B: The history of cancer epigenetics. Nat Rev Cancer 4:143-153, 2004
5. Strahl BD, Allis CD: The language of covalent histone modifications. Nature 403:41-45, 2000
6. Jenuwein T, Allis CD: Translating the histone code. Science 293:1074-1080, 2001
7. Roberts CW, Orkin SH: The SWI/SNF complex-Chromatin and cancer. Nat Rev Cancer 4:133-142, 2004
8. Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116:281-297, 2004
9. Vogelstein B, Kinzler KW: Cancer genes and the pathways they control. Nat Med 10:789-799, 2004
10. Lund AH, van Lohuizen M: Epigenetics and cancer. Genes Dev 18:2315-2335, 2004
11. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100:57-70, 2000
12. Redner RL, Wang J, Liu JM: Chromatin remodeling and leukemia: New therapeutic paradigms. Blood 94:417-428, 1999
13. Jones LK, Saha V: Chromatin modification, leukaemia and implications for therapy. Br J Haematol 118:714-727, 2002
14. Herman JG, Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349:2042-2054, 2003
15. Issa JP: CpG island methylator phenotype in cancer. Nat Rev Cancer 4:988-993, 2004
16. Robertson KD: DNA methylation, methyltransferases, and cancer. Oncogene 20:3139-3155, 2001
17. Richardson B: Impact of aging on DNA methylation. Ageing Res Rev 2:245-261, 2003
18. Feinberg AP, Vogelstein B: Hypomethylation of ras oncogenes in primary human cancers. Biochem Biophys Res Commun 111:47-54, 1983
19. Hanada M, Delia D, Aiello A, et al: bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 82:1820-1828, 1993
20. Oshimo Y, Nakayama H, Ito R, et al: Promoter methylation of cyclin D2 gene in gastric carcinoma. Int J Oncol 23:1663-1670, 2003
21. Ehrlich M: DNA methylation in cancer: Too much, but also too little. Oncogene 21:5400-5413, 2002
22. Chen RZ, Pettersson U, Beard C, et al: DNA hypomethylation leads to elevated mutation rates. Nature 395:89-93, 1998
23. Gaudet F, Hodgson JG, Eden A: Induction of tumors in mice by genomic hypomethylation. Science 300:489-492, 2003
24. Kane MF, Loda M, Gaida GM, et al: Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 57:808-811, 1997
25. Herman JG, Umar A, Polyak K, et al: Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A 95:6870-6875, 1998
26. Toyota M, Ahuja N, Ohe-Toyota M, et al: CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 96:8681-8686, 1999
27. Toyota M, Ahuja N, Suzuki H, et al: Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res 59:5438-5442, 1999
28. Nakamura M, Watanabe T, Yonekawa Y, et al: Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C → A:T mutations of the TP53 tumor suppressor gene. Carcinogenesis 22:1715-1719, 2001
29. Esteller M, Toyota M, Sanchez-Cespedes M, et al: Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res 60:2368-2371, 2000
30. Sheikhha MH, Tobal K, Liu Yin JA, et al: High level of microsatellite instability but not hypermethylation of mismatch repair genes in therapy-related and secondary acute myeloid leukaemia and myelodysplastic syndrome. Br J Haematol 117:359-365, 2002
31. Nakagawa H, Chadwick RB, Peltomaki P, et al: Loss of imprinting of the insulin-like growth factor II gene occurs by biallelic methylation in a core region of H19-associated CTCF-binding sites in colorectal cancer. Proc Natl Acad Sci U S A 98:591-596, 2001
32. Rountree MR, Bachman KE, Baylin SB: DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat Genet 25:269-277, 2000
33. Nan X, Ng HH, Johnson CA, et al: Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393:386-389, 1998
34. Robertson KD, Ait-Si-Ali S, Yokochi T, et al: DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat Genet 25:338-342, 2000
35. Fuks F, Burgers WA, Brehm A, et al: DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat Genet 24:88-91, 2000
36. Burgers WA, Fuks F, Kouzarides T: DNA methyltransferases get connected to chromatin. Trends Genet 18:275-277, 2002
37. Di Croce L, Raker VA, Corsaro M, et al: Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 295:1079-1082, 2002
38. Jones PA: The DNA methylation paradox. Trends Genet 15:34-37, 1999
39. Kass SU, Pruss D, Wolffe AP: How does DNA methylation repress transcription? Trends Genet 13:444-449, 1997
40. Nguyen CT, Gonzales FA, Jones PA: Altered chromatin structure associated with methylation-induced gene silencing in cancer cells: Correlation of accessibility, methylation, MeCP2 binding and acetylation. Nucleic Acids Res 29:4598-4606, 2001
41. Nakagawachi T, Soejima H, Urano T, et al: Silencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer. Oncogene 22:8835-8844, 2003
42. Ivanov MA, Lamrihi B, Szyf M, et al: Enhanced antitumor activity of a combination of MBD2-antisense electrotransfer gene therapy and bleomycin electrochemotherapy. J Gene Med 5:893-899, 2003
43. Sansom OJ, Berger J, Bishop SM, et al: Deficiency of Mbd2 suppresses intestinal tumorigenesis. Nat Genet 34:145-147, 2003
44. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704-707, 1993
45. Otterson GA, Khleif SN, Chen W, et al: CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2′deoxycytidine. Oncogene 11:1211-1216, 1995
46. Myohanen SK, Baylin SB, Herman JG: Hypermethylation can selectively silence individual p16ink4A alleles in neoplasia. Cancer Res 58:591-593, 1998
47. Lee WH, Morton RA, Epstein JI, et al: Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci U S A 91:11733-11737, 1994
48. Millar DS, Ow KK, Paul CL, et al: Detailed methylation analysis of the glutathione S-transferase pi (GSTP1) gene in prostate cancer. Oncogene 18:1313-1324, 1999
49. Stirzaker C, Millar DS, Paul CL, et al: Extensive DNA methylation spanning the Rb promoter in retinoblastoma tumors. Cancer Res 57:2229-2237, 1997
50. Melki JR, Vincent PC, Clark SJ: Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. Cancer Res 59:3730-3740, 1999
51. Aggerholm A, Guldberg P, Hokland M, et al: Extensive intra- and interindividual heterogeneity of p15INK4B methylation in acute myeloid leukemia. Cancer Res 59:436-441, 1999
52. Cameron EE, Baylin SB, Herman JG: p15(INK4B) CpG island methylation in primary acute leukemia is heterogeneous and suggests density as a critical factor for transcriptional silencing. Blood 94:2445-2451, 1999
53. Wolff L, Garin MT, Koller R, et al: Hypermethylation of the Ink4b locus in murine myeloid leukemia and increased susceptibility to leukemia in p15(Ink4b)-deficient mice. Oncogene 22: 9265-9274, 2003
54. Mhawech P, Saleem A: Myelodysplastic syndrome: Review of the cytogenetic and molecular data. Crit Rev Oncol Hematol 40:229-238, 2001
55. Quesnel B, Guillerm G, Vereecque R, et al: Methylation of the p15 (INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 91:2985-2990, 1998
56. Koduru PR, Zariwala M, Soni M, et al: Deletion of cyclin-dependent kinase 4 inhibitor genes P15 and P16 in non-Hodgkin's lymphoma. Blood 86:2900-2905, 1995
57. Toyota M, Kopecky KJ, Toyota MO, et al: Methylation profiling in acute myeloid leukemia. Blood 97:2823-2829, 2001
58. Uchida T, Kinoshita T, Nagai H, et al: Hypermethylation of the p15INK4B gene in myelodysplastic syndromes. Blood 90:1403-1409, 1997
59. Drexler HG: Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia 12:845-859, 1998
60. Tschan MP, Vonlanthen S, Cajot JF, et al: Different p16INK4a and p14ARF expression patterns in acute myeloid leukaemia and normal blood leukocytes. Leuk Lymphoma 42:1077-1087, 2001
61. Leone G, Teofili L, Voso MT, et al: DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica 87:1324-1341, 2002
62. Shen L, Toyota M, Kondo Y, et al: Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. Blood 101: 4131-4136, 2003
63. Teofili L, Martini M, Luongo M, et al: Hypermethylation of GpG islands in the promoter region of p15INK4b in acute promyelocytic leukemia represses p15INK4b expression and correlates with poor prognosis. Leukemia 17:919-924, 2003
64. Garcia-Manero G, Daniel J, Smith TL, et al: DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clin Cancer Res 8:2217-2224, 2002
65. Gilbert J, Gore SD, Herman JG, et al: The clinical application of targeting cancer through histone acetylation and hypomethylation. Clin Cancer Res 10:4589-4596, 2004
66. Goffin J, Eisenhauer E: DNA methyltransferase inhibitors-state of the art. Ann Oncol 13:1699-1716, 2002
67. Das PM, Singal R: DNA methylation and cancer. J Clin Oncol 22:4632-4642, 2004
68. Issa JP: Decitabine. Curr Opin Oncol 15: 446-451, 2003
69. Bouchard J, Momparler RL: Incorporation of 5-Aza-2′-deoxycytidine- 5′-triphosphate into DNA. Interactions with mammalian DNA polymerase alpha and DNA methylase. Mol Pharmacol 24:109-114, 1983
70. Santi DV, Garrett CE, Barr PJ: On the mechanism of inhibition of DNA-cytosine methyltransferases by cytosine analogs. Cell 33:9-10, 1983
71. Momparler RL, Samson J, Momparler LF, et al: Cell cycle effects and cellular pharmacology of 5-aza-2′-deoxycytidine. Cancer Chemother Pharmacol 13:191-194, 1984
72. Santi DV, Norment A, Garrett CE: Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc Natl Acad Sci U S A 81:6993-6997, 1984
73. Momparler RL, Bouchard J, Samson J: Induction of differentiation and inhibition of DNA methylation in HL-60 myeloid leukemic cells by 5-AZA-2′-deoxycytidine. Leuk Res 9:1361-1366, 1985
74. Pinto A, Attadia V, Fusco A, et al: 5-Aza-2′-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. Blood 64:922-929, 1984
75. Bender CM, Pao MM, Jones PA: Inhibition of DNA methylation by 5-aza-2′-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res 58:95-101, 1998
76. Lubbert M: DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: Clinical results and possible mechanisms of action. Curr Top Microbiol Immunol 249:135-164, 2000
77. Issa JP, Garcia-Manero G, Giles FJ, et al: Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′- deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103:1635-1640, 2004
78. Daskalakis M, Nguyen TT, Nguyen C, et al: Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment. Blood 100:2957-2964, 2002
79. Juttermann R, Li E, Jaenisch R: Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci U S A 91:11797-11801, 1994
80. Cheng JC, Matsen CB, Gonzales FA, et al: Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst 95:399-409, 2003
81. Cheng JC, Yoo CB, Weisenberger DJ, et al: Preferential response of cancer cells to zebularine. Cancer Cell 6:151-158, 2004
82. Stewart DJ, Donehower RC, Eisenhauer EA, et al: A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly. Ann Oncol 14:766-774, 2003
83. Karon M, Sieger L, Leimbrock S, et al: 5-Azacytidine: A new active agent for the treatment of acute leukemia. Blood 42:359-365, 1973
84. McCredie KB, Bodey GP, Burgess MA, et al: Treatment of acute leukemia with 5-azacytidine (NSC-102816). Cancer Chemother Rep 57:319-323, 1973
85. Levi JA, Wiernik PH: A comparative clinical trial of 5-azacytidine and guanazole in previously treated adults with acute nonlymphocytic leukemia. Cancer 38:36-41, 1976
86. Saiki JH, McCredie KB, Vietti TJ, et al: 5-azacytidine in acute leukemia. Cancer 42:2111-2114, 1978
87. Saiki JH, Bodey GP, Hewlett JS, et al: Effect of schedule on activity and toxicity of 5-azacytidine in acute leukemia: a Southwest Oncology Group Study. Cancer 47:1739-1742, 1981
88. Chitambar CR, Libnoch JA, Matthaeus WG, et al: Evaluation of continuous infusion low-dose 5-azacytidine in the treatment of myelodysplastic syndromes. Am J Hematol 37:100-104, 1991
89. Silverman LR, Holland JF, Weinberg RS, et al: Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 7: 21-29, 1993 (suppl 1)
90. Silverman L: DNA methyltransferase inhibitors in myelodysplastic syndrome, in Rowe JM (ed): Best Practice & Research Clinical Haematology. Oxford, UK, Alden Press, 2004, pp 595-611
91. Gryn J, Zeigler ZR, Shadduck RK, et al: Treatment of myelodysplastic syndromes with 5-azacytidine. Leuk Res 26:893-897, 2002
92. Silverman LR, Demakos EP, Peterson BL, et al: Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B. J Clin Oncol 20:2429-2440, 2002
93. Momparler RL, Rivard GE, Gyger M: Clinical trial on 5-aza-2′- deoxycytidine in patients with acute leukemia. Pharmacol Ther 30:277-286, 1985
94. Petti MC, Mandelli F, Zagonel V, et al: Pilot study of 5-aza-2′-deoxycytidine (Decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: Preliminary results. Leukemia 7:36-41, 1993 (suppl 1)
95. Kantarjian HM, O'Brien SM, Estey E, et al: Decitabine studies in chronic and acute myelogenous leukemia. Leukemia 11:S35-S36, 1997 (suppl 1)
96. Kantarjian HM, O'Brien SM, Keating M, et al: Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia. Leukemia 11:1617-1620, 1997
97. Sacchi S, Kantarjian HM, O'Brien S, et al: Chronic myelogenous leukemia in nonlymphoid blastic phase: Analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer 86:2632-2641, 1999
98. Issa JP, Gharibyan V, Jelinek J, et al: Hypomethylation dynamics following decitabine therapy in chronic myelogenous leukemia. Blood 104:2956, 2004
99. Wijermans P, Lubbert M, Verhoef G, et al: Low-dose 5-aza-2′- deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: A multicenter phase II study in elderly patients. J Clin Oncol 18:956-962, 2000
100. Kantarjian HM, Ravandi F, O'Brien S, et al: Decitabine low-dose schedule (100 mg/m2/ course) in myelodysplastic syndrome (MDS). Comparison of 3 different dose schedules. Blood 104:1437, 2004
101. Saba H, Rosenfeld C, Issa JP, et al: First Report of the Phase III North American Trial of Decitabine in Advanced Myelodysplastic Syndrome (MDS). Blood 104:67, 2004
102. Israili ZH, Vogler WR, Mingioli ES, et al: The disposition and pharmacokinetics in humans of 5-azacytidine administered intravenously as a bolus or by continuous infusion. Cancer Res 36:1453-1461, 1976
103. Troetel WM, Weiss AJ, Stambaugh JE: Absorption, distribution, and excretion of 5-azacytidine (NSC-1028116) in man. Cancer Chemother Rep 56:405-411, 1972
104. Vogler WR, Miller DS, Keller JW: 5-Azacytidine (NSC 102816): A new drug for the treatment of myeloblastic leukemia. Blood 48:331-337, 1976
105. Kornblith AB, Herndon JE, Silverman LR, et al: Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: A Cancer and Leukemia Group B study. J Clin Oncol 20:2441-2452, 2002
106. Aparicio A, Weber JS: Review of the clinical experience with 5-azacytidine and 5-aza-2′-deoxycytidine in solid tumors. Curr Opin Investig Drugs 3:627-633, 2002
107. Wijermans P, Krulder JW, Huijgens PC, et al: Continuous infusion of low-dose 5-Aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 11:1-5, 1997
108. Momparler RL: Molecular, cellular and animal pharmacology of 5-aza-2′-deoxycytidine. Pharmacol Ther 30:287-299, 1985
109. Vesely J: Mode of action and effects of 5-azacytidine and of its derivatives in eukaryotic cells. Pharmacol Ther 28:227-235, 1985
110. Kantharidis P, EI Osta A, deSilva M, et al: Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance. Clin Cancer Res 3:2025-2032, 1997
111. Wade PA: Methyl CpG-binding proteins and transcriptional repression. Bioessays 23: 1131-1137, 2001
112. Liu PQ, Rebar EJ, Zhang L, et al: Regulation of an endogenous locus using a panel of designed zinc finger proteins targeted to accessible chromatin regions. Activation of vascular endothelial growth factor A. J Biol Chem 276: 11323-11334, 2001
113. Felsenfeld G, Groudine M: Controlling the double helix. Nature 421:448-453, 2003
114. Khorasanizadeh S: The nucleosome: From genomic organization to genomic regulation. Cell 116:259-272, 2004
115. Turner BM: Memorable transcription. Nat Cell Biol 5:390-393, 2003
116. Jenuwein T, Allis CD: Translating the histone code. Science 293:1074-1080, 2001
117. Schreiber SL, Bernstein BE: Signaling network model of chromatin. Cell 111:771-778, 2002
118. Schübeler D, MacAlpine DM, Scalzo D, et al: The histone modification pattern of active genes revealed through genome-wide chromatin analysis of a higher eukaryote. Genes Dev 18: 1263-1271, 2004
119. Cress WD, Seto E: Histone deacetylase, transcription control and cancer. J Cell Physiol 184:1-16, 2000
120. Marks P, Rifkind RA, Richon VM, et al: Histone deacetylases and cancer: Causes and therapies. Nat Rev Cancer 1:194-202, 2001
121. Johnstone RW, Licht JD: Histone deacetylase inhibitors in cancer therapy: Is transcription the primary target? Cancer Cell 4:13-18, 2003
122. Lindemann RK, Gabrielli B, Johnstone RW: Histone-deacetylase inhibitors for the treatment of cancer. Cell Cycle 3:779-788, 2004
123. Haggarty SJ, Koeller KM, Wong JC, et al: Domain-selective amall-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci U S A 100: 4389-4394, 2003
124. Wolf D, Rodova M, Miska EA, et al: Acetylation of beta-catenin by CREB-binding protein (CBP). J Biol Chem 277:25562-25567, 2002
125. Bannister AJ, Miska EA, Gorlich D, et al: Acetylation of importin-alpha nuclear import factors by CBP/p300. Curr Biol 10:467-470, 2000
126. Blander G, Zalle N, Daniely Y, et al: DNA damage-induced translocation of the Werner helicase is regulated by acetylation. J Biol Chem 277:50934-50940, 2002
127. Cohen HY, Lavu S, Bitterman KJ, et al: Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol Cell 13:627-638, 2004
128. Fuino L, Bali P, Wittmann S, et al: Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol Cancer Ther 2:971-984, 2003
129. Hubbert C, Guardiola A, Shao R, et al: HDAC6 is a microtubule-associated deacetylase. Nature 417:455-458, 2002
130. Yang XJ: The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases. Nucleic Acids Res 32:959-976, 2004
131. Blobel GA: CREB-binding protein and p300: Molecular integrators of hematopoietic transcription. Blood 95:745-755, 2000
132. Gayther SA, Batley SJ, Linger L, et al: Mutations truncating the EP300 acetylase in human cancers. Nat Genet 24:300-303, 2000
133. Borrow J, Stanton VP Jr, Andresen JM, et al: The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet 14:33-41, 1996
134. Sobulo OM, Borrow J, Tomek R, et al: MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3). Proc Natl Acad Sci U S A 94:8732-8737, 1997
135. Panagopoulos I, Fioretos T, Isaksson M, et al: Fusion of the MORF and CBP genes in acute myeloid leukemia with the t(10;16)(q22;p13). Hum Mol Genet 10:395-404, 2001
136. So CW, Cleary MJ: Dimerization a versatile switch for oncogenesis. Blood 104:919-922, 2004
137. Scandura JM, Boccuni P, Cammenga J, et al: Transcription factor fusions in acute leukemia: Variations on a theme. Oncogene 21:3422-3444, 2002
138. Durst KL, Hiebert SW: Role of RUNX family members in transcriptional repression and gene silencing. Oncogene 23:4220-4224, 2004
139. Phan RT, Dalla-Favera R: The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature 432:635-639, 2004
140. Fujita N, Jaye DL, Geigerman C, et al: MTA3 and the Mi-2/NuRD complex regulate cell fate during B lymphocyte differentiation. Cell 119:75-86, 2004
141. Polo JM, Dell'Osa T, Ranuncolo SM, et al: Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat Med 10:1329-1334, 2004
142. Marks PA, Richon VA, Rifkind RA: Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92:1210-1216, 2000
143. Frye RA: Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity. Biochem Biophys Res Commun 260:273-279, 1999
144. North BJ, Marshall BL, Borra MT, et al: The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol Cell 11:437-444, 2003
145. Luo J, Nikolaev AY, Imai S, et al: Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 107:137-148, 2001
146. Van Lint C, Emiliani S, Verdin E: The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr 5:245-253, 1996
147. Huang L, Pardee AB: Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Mol Med 6:849-866, 2000
148. Glaser KB, Staver MJ, Waring JF, et al: Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: Defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2:151-163, 2003
149. Mitsiades CS, Mitsiades NS, McMullan CJ, et al: Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications. Proc Natl Acad Sci U S A 101:540-545, 2004
150. Richon VM, Sandhoff TW, Rifkind RA, et al: Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A 97:10014-10019, 2000
151. Vrana JA, Decker RH, Johnson CR, et al: Induction of apoptosis in U937 human leukemia cells by Suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene 18:7016-7025, 1999
152. Nimmanapalli R, Fuino L, Stobaugh C, et al: Co-treatment with the histone deacetylase inhibitor Suberoylanilide hydroxamic acid (SAHA) enhances Gleevec-induced apoptosis of Bcr-Abl positive human acute leukemia cells. Blood 101: 3236-3239, 2003
153. Blagosklonny MV, Robey R, Sackett DL, et al: Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol Cancer Ther 1:937-941, 2002
154. Gui CY, Ngo L, Xu WS, et al: Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci U S A 101:1241-1246, 2004
155. Sandor V, Senderowicz A, Mertins S, et al: P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br J Cancer 83:817-825, 2000
156. Sambucetti LC, Fischer DD, Zabludoff S, et al: Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J Biol Chem 274: 34940-34947, 1999
157. Wharton W, Savell J, Cress WD, et al: Inhibition of mitogenesis in Balb/c-3T3 cells by trichostatin A. multiple alterations in the induction and activation of cyclin-cyclin-dependent kinase complexes. J Biol Chem 275:33981-33987, 2000
158. Classon M, Harlow E: The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer 2:910-917, 2002
159. Chen Z, Clark S, Birkeland M, et al: Induction and superinduction of growth arrest and DNA damage gene 45 (GADD45) alpha and beta messenger RNAs by histone deacetylase inhibitors trichostatin A (TSA) and butyrate in SW620 human colon carcinoma cells. Cancer Lett 188:127-140, 2002
160. Takakura M, Kyo S, Sowa Y, et al: Telomerase activation by histone deacetylase inhibitor in normal cells. Nucleic Acids Res 29: 3006-3011, 2001
161. Gore SD, Weng LJ, Zhai S, et al: Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res 7: 2330-2339, 2001
162. Richon VM, Webb Y, Merger R, et al: Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci U S A 93:5705-5708, 1996
163. Munster PN, Troso-Sandoval T, Rosen N, et al: The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 61:8492-8497, 2001
164. Yu KH, Weng LJ, Fu S, et al: Augmentation of phenylbutyrate-induced differentiation of myeloid leukemia cells using all-trans retinoic acid. Leukemia 13:1258-1265, 1999
165. Archer SY, Meng S, Shei A, et al: p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci U S A 95:6791-6796, 1998
166. He LZ, Tolentino T, Grayson P, et al: Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest 108:1321-1330, 2001
167. Ferrara FF, Fazi F, Bianchini A, et al: Histone deacetylase-targed treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res 61:2-7, 2001
168. Liu S, Klisovic MI, Shen T, et al: Promotes gene expression by disrupting the DNA binding of the AML1/ETO and HDAC1 represser complex. Blood 104:4386, 2004
169. Gottlicher M, Minucci S, Zhu P, et al: Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20:6969-6978, 2001
170. Mielnicki LM, Ying AM, Head KL, et al: Epigenetic regulation of gelsolin expression in human breast cancer cells. Exp Cell Res 249: 161-176, 1999
171. Ruefli AA, Ausserlechner MJ, Bernhard D, et al: The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci U S A 98:10833-10838, 2001
172. Quo F, Sigua C, Tao J, et al: Co-treatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/TRAIL-induced death inducing signaling complex and apoptosis of human acute leukemia cells. Cancer Res 64:2580-2589, 2004
173. Rosato RR, Almenara JA, Dai Y, et al: Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol Cancer Ther 2:1273-1284, 2003
174. Peart MJ, Tainton KM, Ruefli AA, et al: Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 63: 4460-4471, 2003
175. Bhalla K: Unpublished observation, 2005
176. Mitsiades N, Mitsiades CS, Richardson PG, et al: Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 101:4055-4062, 2003
177. Henderson C, Mizzau M, Paroni G, et al: Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA). J Biol Chem 278: 12579-12589, 2003
178. Burgess AJ, Pavey S, Warrener R, et al: Up-regulation of p21(WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity. Mol Pharmacol 60:828-837, 2001
179. Click RD, Swendeman SL, Coffey DC, et al: Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. Cancer Res 59:4392-4399, 1999
180. Aron JL, Parthun MR, Marcucci G, et al: Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. Blood 102:652-658, 2003
181. Insinga A, Monestiroli S, Ronzoni S, et al: Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 11:71-76, 2005
182. Nebbioso A, Clarke N, Voltz E, et al: Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 11:77-84, 2005
183. Butler LM, Zhou X, Xu WS, et al: The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci U S A 99:11700-11705, 2002
184. Shao Y, Gao Z, Marks PA, et al: Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci U S A 101:18030-18035, 2004
185. Yu X, Guo ZS, Marcu MG, et al: Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells of depsipeptide FR901228. J Natl Cancer Inst 94:504-513, 2002
186. Nimmanapalli R, Fuino L, Bali P, et al: Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or-refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res 63:5126-5135, 2003
187. Yao Q, Nishiuchi R, Li Q, et al: FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases. Clin Cancer Res 9:4483-4493, 2003
188. George P, Bali P, Annavarapu S, et al: Combination of histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 105:1768-1776, 2005
189. Bali P, George P, Cohen P, et al: Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3. Clin Cancer Res 10:4991-4997, 2004
190. Kim MS, Kwon HJ, Lee YM, et al: Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 7:437-443, 2001
191. Mie Lee Y, Kim SH, Kim HS, et al: Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1 alpha activity. Biochem Biophys Res Commun 300:241-246, 2003
192. Deroanne CF, Bonjean K, Servotte S, et al: Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21:427-436, 2002
193. Qian DZ, Wang X, Kachhap SK, et al: The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res 64: 6626-6634, 2004
194. Rosato RR, Wang Z, Gopalkrishnan RV, et al: Evidence of a functional role for the cyclin-dependent kinase-inhibitor p21WAF1/CIP1/ MDA6 in promoting differentiation and preventing mitochondrial dysfunction and apoptosis induced by sodium butyrate in human myelomonocytic leukemia cells (U937). Int J Oncol 19: 181-191, 2001
195. DiGiuseppe JA, Weng LJ, Yu KH, et al: Phenylbutyrate-induced G1 arrest and apoptosis in myeloid leukemia cells: Structure-function analysis. Leukemia 13:1243-1253, 1999
196. Kuendgen A, Strupp C, Aivado M, et al: Treatment of myelodysplastic syndromes with valproic acid alone or in combination with alltrans retinoic acid. Blood 104:1266-1269, 2004
197. Nervi C, Lo Coco F, Minucci S, et al: Valproic acid plus retinoic acid induce myeloid differentiation in chemotherapy-resistant acute myeloid leukemia patients. Blood 104:1805, 2004
198. Kelly WK, Richon VM, O'Connor O, et al: Phase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 9:3578-3588, 2003
199. Richardson P, Schlossman RB, Mitsiades CS, et al: Phase I clnical trial of oral administration of the histone deacetylase (HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA) in patients with relapsed/refractory multiple myeloma (MM). Blood 104:1503, 2004
200. Duvic M, Talpur R, Chiao N, et al: Phase II trial of oral suberoylanilide hydroxamic acid (SAHA) for cutaneous T-cell lymphorna (CTCL) and peripheral T-cell lymphoma (PTCL). Blood 102:625, 2003
201. Reddy P, Maeda Y, Hotary K, et al: Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci U S A 101:3921-3926, 2004
202. Remiszewski SW: The Discovery of NVP-LAQ824: From concept to clinic. Curr Med Chem 10:2393-2402, 2003
203. Atadja P, Gao L, Kwon P, et al: Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824. Cancer Res 64:689-695, 2004
204. Weisberg E, Catley L, Kujawa J, et al: Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo. Leukemia 18:1951-1963, 2004
205. Ottmann OG, Deangelo DJ, Stone RM, et al: A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of a novel histone deacetylase inhibitor LAQ824 in patients with hematologic malignancies. J Clin Oncol 22:201s, 2004 (abstr 3024; suppl)
206. Giles F, Fischer T, Cortes J, et al: A phase I/II study of intravenous LBH589, a novel histone deacetylase (HDAC) inhibitor, in patients (pts) with advanced hematologic malignancies. Blood 104:1802, 2004
207. Suzuki T, Ando T, Tsuchiya K, et al: Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J Med Chem 42:3001-3003, 1999
208. Saito A, Yamashita T, Mariko Y, et al: A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci U S A 96:4592-4597, 1999
209. Lee BI, Park SH, Kim JW, et al: MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor beta type II receptor expression in human breast cancer cells. Cancer Res 61:931-934, 2001
210. Jaboin J, Wild J, Hamidi H, et al: MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res 62: 6108-6115, 2002
211. Lucas DM, Davis ME, Parthun MR, et al: The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia 18:1207-1214, 2004
212. Ungerstedt JS, Sowa Y, Xu WS, et al: Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci U S A 102:673-678, 2005
213. Ryan QC, Headlee D, Sparreboom A, et al: A phase I trial of an oral histone deacetylase inhibitor, MS-275, in advanced solid tumor and lymphoma patients. Proc Am Soc Clin Oncol 21:200, 2003 (abstr 802)
214. Prakash S, Foster BJ, Meyer M, et al: Chronic oral administration of CI-994: A phase 1 study. Invest New Drugs 19:1-11, 2001
215. Sasakawa Y, Naoe Y, Inoue T, et al: Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo. Biochem Pharmacol 64:1079-1090, 2002
216. Han JW, Ahn SH, Park SH, et al: Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/ Cip1 and gelsolin. Cancer Res 60:6068-6074, 2000
217. Byrd JC, Shinn C, Ravi R, et al: Depsipeptide (FR901228): A novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. Blood 94: 1401-1408, 1999
218. Furumai R, Matsuyama A, Kobashi N, et al: FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 62:4916-4821, 2002
219. Tabe Y, Contractor R, Radke S, et al: Histone deacetylase inhibitor Depsipeptide (FK228) induces apoptosis through histone acetylation and upregulation of annexin A1 in AML-ETO expressing kasumi-1 cells. Blood 104:4343, 2004
220. Kwon HJ, Kim MJ, Nakajima H, et al: Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis. Int J Cancer 97:290-296, 2002
221. Piekarz R, Bates S: A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr Pharm Des 10:2289-2298, 2004
222. Odenike OM, Alkan S, Sher D: The histone deacetylase inhibitor Depsipeptide has differential activity in specific cytogenetic subsets of acute myeloid leukemia (AML). Blood 104:264, 2004
223. Paner GP, Alkan S: Analysis of the effect of the novel histone deacetylase inhibitor, Depsipeptide (FK288/FR901228) on mantle cell lymphoma. Blood 104:2499, 2004
224. Kawamata N, Koeffler HP: Mantle cell lymphoma: SAHA blocks Akt/mTOR pathway and reduces cyclin D1 protein levels by affecting translation. Blood 104:3293, 2004
225. Qiu L, Kelso MJ, Hansen C, et al: Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate. Br J Cancer 80:1252-1258, 1999
226. Brinkmann H, Dahler AL, Popa C, et al: Histone hyperacetylation induced by histone deacetylase inhibitors is not sufficient to cause growth inhibition in human dermal fibroblasts. J Biol Chem 276:22491-22499, 2001
227. Zhang XD, Gillespie SK, Borrow JM, et al: The histone deacetylase inhibitor suberic bishydroxamate: A potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis. Biochem Pharmacol 66: 1537-1545, 2003
228. Sherr CJ: Principles of tumor suppression. Cell 116:235-246, 2004
229. John AM, Thomas NS, Mufti GJ, et al: Targeted therapies in myeloid leukemia. Semin Cancer Biol 14:41-62, 2004
230. Nakata S, Yoshida T, Horinaka M, et al: Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 23:6261-6271, 2004
231. Fahrner JA, Eguchi S, Herman JG, et al: Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res 62:7213-7218, 2002
232. Bachman KE, Park BH, Rhee I, et al: Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell 3:89-95, 2003
233. Stirzaker C, Song JZ, Davidson B, et al: Transcriptional gene silencing promotes DNA hypermethylation through a sequential change in chromatin modifications in cancer cells. Cancer Res 64:3871-3877, 2004
234. Nguyen CT, Weisenberger DJ, Velicescu M, et al: Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2′-deoxycytidine. Cancer Res 62:6456-6461, 2002
235. Zhu WG, Lakshmanan RR, Beal MD, et al: DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res 61:1327-1333, 2001
236. Cameron EE, Bachman KE, Myohanen S, et al: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21:103-107, 1999
237. Belinsky SA, Klinge DM, Stidley CA, et al: Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res 63:7089-7093, 2003
238. Zhu WG, Otterson GA: The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr Med Chem Anti-Canc Agents 3:187-199, 2003
239. Zelent A, Waxman S, Carducci M, et al: State of the translational science: Summary of Baltimore workshop on gene re-expression as a therapeutic target in cancer January 2003. Clin Cancer Res 10:4622-4629, 2004
240. Gore SD, Baylin SB, Dauses T, et al: Changes in promoter methylation and gene expression in patients with MDS and MDS-AML treated with 5-Azacitidine and sodium phenylbutyrate. Blood 104:469, 2004
241. Garcia-Manero G, Kantarjian H, Sanchez-Gonzalez B, et al: Results of a phase I/II study of the combination of 5-aza-2′-deoxycytidine (DAC) and valproic acid (VPA) in patients (pts) with leukemia. Blood 104:263, 2004
242. Coffey DC, Kutko MC, Glick RD, et al: Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro. Med Pediatr Oncol 35:577-581, 2000
243. Coffey DC, Kutko MC, Glick RD, et al: The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. Cancer Res 61:3591-3594, 2001
244. Zhai S, Senderowicz AM, Sausville EA, et al: Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development. Ann Pharmacother 36:905-911, 2002
245. Almenara J, Rosato R, Grant S: Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). Leukemia 16:1331-1343, 2002
246. Rosato RR, Almenara JA, Cartee L, et al: The cyclin-dependent kinase inhibitor flavopiridol disrupts sodium butyrate-induced p21WAF1/ CIP1 expression and maturation while reciprocally potentiating apoptosis in human leukemia cells. Mol Cancer Ther 1:253-266, 2002
247. Nguyen DM, Schrump WD, Chen GA, et al: Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells. Clin Cancer Res 10:1813-1825, 2004
248. Gao N, Dai Y, Rahmani M, et al: Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol. Mol Pharmacol 66:956-963, 2004
249. Wittmann S, Bali P, Donapaty S, et al: Flavopiridol downregulates antiapoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis. Cancer Res 63:93-99, 2003
250. Gojo I, Zhang B, Fenton RG: The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin Cancer Res 8:3527-3538, 2002
251. Wall NR, O'Connor DS, Plescia J, et al: Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res 63:230-235, 2003
252. Bali P, Pranpat M, Swaby R, et al: Suberoylanilide hydroxamic acid (SANA) attenuates Her-2 levels and exerts synergistic cytotoxicity with trastuzumab or docetaxel against breast cancer cells with amplification of Her-2. Manuscript submitted, 2004
253. Huang Y, Waxman S: Enhanced growth inhibition and differentiation of fluorodeoxyuridine-treated human colon carcinoma cells by phenylbutyrate. Clin Cancer Res 4:2503-2509, 1998
254. Kim MS, Blake M, Baek JH, et al: Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 63:7291-7300, 2003
255. Kurz EU, Wilson SE, Leader KB, et al: The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase II alpha expression and confers hypersensitivity to etoposide in human leukemic cell lines. Mol Cancer Ther 1:121-131, 2001
256. Marchion DC, Bicaku E, Daud AI, et al: Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem 92:223-237, 2004
257. Witzig TE, Timm M, Stenson M, et al: Induction of apoptosis in malignant B cells by phenylbutyrate or phenylacetate in combination with chemotherapeutic agents. Clin Cancer Res 6:681-692, 2000
258. Rosato RR, Almenara JA, Dai Y, et al: Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol Cancer Ther 2:1273-1284, 2003
259. Rahmani M, Yu C, Dai Y, et al: Coadministration of the heat shock protein 90 antagonist 17-allylamino-17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells. Cancer Res 63:8420-8427, 2003
260. Shah NP, Tran C, Lee FY, et al: Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305:399-401, 2004
261. Sawyers CL, Shah NP, Kantarjian HM, et al: Hematologic and cytogenetic responses in imatinib-resistant chronic phase chronic myeloid leukemia patients treated with the dual SRC/ ABL kinase inhibitor BMS-354825: Results from a phase I dose escalation study. Blood 104:1, 2004
262. Adams J: The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5:417-421, 2004
263. Yu C, Rahmani M, Conrad D, et al: The proteasorne inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood 102:3765-3774, 2003
264. Pei XY, Dai Y, Grant S: Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 10:3839-3852, 2004
265. Rea S, Eisenhaber F, O'Carroll D, et al: Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature 406:593-599, 2000
266. Schneider R, Bannister AJ, Kouzarides T: Unsafe SETs: Histone lysine methyltransferases and cancer. Trends Biochem Sci 27:396-402, 2002
267. Bannister AJ, Zegerman P, Partridge JF, et al: Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain. Nature 410:120-124, 2001
268. Peters AH, O'Carroll D, Scherthan H, et al: Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell 107:323-337, 2001
269. Kim KC, Geng L, Huang S: Inactivation of a histone methyltransferase by mutations in human cancers. Cancer Res 63:7619-7623, 2003
270. Sitailo S, Sood R, Barton K, et al: Forced expression of the leukemia-associated gene EVI1 in ES cells: A model for myeloid leukemia with 3q26 rearrangements. Leukemia 13:1639-1645, 1999
271. Barjesteh van Waalwijkvan Doorn-Khosrovani S, Erpelinck C, van Putten WL, et al: High EVI1 expression predicts poor survival in acute myeloid leukemia: A study of 319 de novo AML patients. Blood 101:837-845, 2003
272. Bergsagel PL, Kuehl WM: Chromosome translocations in multiple myeloma. Oncogene 20:5611-5622, 2001
273. Valk-Lingbeek ME, Bruggeman SW, van Lohuizen M: Stem cells and cancer: The polycomb connection. Cell 118:409-418, 2004
274. Varambally S, Dhanasekaran SM, Zhou M, et al: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419:624-629, 2002
275. Kleer CG, Cao Q, Varambally S, et al: EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 100: 11606-11611, 2003
276. Bracken AP, Pasini D, Capra M, et al: EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 22:5323-5335, 2003
277. Daser A, Rabbitts TH: Extending the repertoire of the mixed-lineage leukemia gene MLL in leukemogenesis. Genes Dev 18:965-974, 2004
278. Milne TA, Briggs SD, Brock HW, et al: MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell 10:1107-1117, 2002
279. Nakamura T, Mori T, Tada S, et al: ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. Mol Cell 10:1119-1128, 2002
280. So CW, Lin M, Ayton PM, et al: Dimerization contributes to oncogenic activation of MLL chimeras in acute leukemias. Cancer Cell 4:99-110, 2003
281. Becker PB, Horz W: ATP-dependent nucleosome remodeling. Annu Rev Biochem 71: 247-273, 2002
282. Betz BL, Strobeck MW, Reisman DN, et al: Re-expression of hSNF5/INI1/BAF47 in pediatric tumor cells leads to G1 arrest associated with induction of p16ink4a and activation of RB. Oncogene 21:5193-5203, 2002
283. Roberts CW, Leroux MM, Fleming MD, et al: Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5. Cancer Cell 2:415-425, 2002
284. Phelan ML, Sif S, Narlikar GJ, et al: Reconstitution of a core chromatin remodeling complex from SWI/SNF subunits. Mol Cell 3: 247-253, 1999
285. Reisman DN, Sciarrotta J, Wang W, et al: Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: Correlation with poor prognosis. Cancer Res 63:560-566, 2003
286. Henikoff S, Furuyama T, Ahmad K: Histone variants, nucleosome assembly and epigenetic inheritance. Trends Genet 20:320-326, 2004
287. Bassing CH, Chua KF, Sekiguchi J, et al: Increased ionizing radiation sensitivity and genomic instability in the absence of histone H2AX. Proc Natl Acad Sci U S A 99:8173-8178, 2002
288. Bassing CH, Suh H, Ferguson DO, et al: Histone H2AX: A dosage-dependent suppressor of oncogenic translocations and tumors. Cell 114:359-370, 2003
289. Celeste A, Difilippantonio S, Difilippantonio MJ, et al: H2AX haploinsufficiency modifies genomic stability and tumor susceptibility. Cell 114:371-383, 2003
290. Rangasamy D, Greaves I, Tremethick DJ: RNA interference demonstrates a novel role for H2A.Z in chromosome segregation. Nat Struct Mol Biol 11:650-655, 2004
291. Yoda K, Ando S, Morishita S, et al: Human centromere protein A (CENP-A) can replace histone H3 in nucleosome reconstitution in vitro. Proc Natl Acad Sci U S A 97:7266-7271, 2000
292. Tomonaga T, Matsushita K, Yamaguchi S, et al: Overexpression and mistargeting of centromere protein-A in human primary colorectal cancer. Cancer Res 63:3511-3516, 2003
293. Tarn W, Hughes SH, Hayward WS, et al: Avian bic, a gene isolated from a common retroviral site in avian leukosis virus-induced lymphomas that encodes a noncoding RNA, cooperates with c-myc in lymphomagenesis and erythroleukemogenesis. J Virol 76:4275-4286, 2002
294. Calin GA, Dumitru CD, Shimizu M, et al: Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 99:15524-15529, 2002
295. Calin GA, Sevignani C, Dumitru CD, et al: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 101:2999-3004, 2004
296. Elbashir SM, Harborth J, Lendeckel W, et al: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494-498, 2001
297. Pal-Bhadra M, Leibovitch BA, Gandhi SG, et al: Heterochromatic silencing and HP1 localization in Drosophila are dependent on the RNAi machinery. Science 303:669-672, 2004
298. Pal-Bhadra M, Bhadra U, Birchler JA: RNAi related mechanisms affect both transcriptional and posttranscriptional transgene silencing in Drosophila. Mol Cell 9:315-327, 2002
299. Soutschek J, Akinc A, Bramlage B, et al: Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432:173-178, 2004
300. Luo RX, Postigo AA, Dean DC: Rb interacts with histone deacetylase to repress transcription. Cell 92:463-473, 1998
301. Dahiya A, Wong S, Gonzalo S, et al: Linking the Rb and polycomb pathways. Mol Cell 8:557-569, 2001
302. Marita M, Nunez S, Heard E, et al: Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 113:703-716, 2003
303. Buyse IM, Shao G, Huang S: The retinoblastoma protein binds to RIZ, a zinc-finger protein that shares an epitope with the adenovirus E1A protein. Proc Natl Acad Sci U S A 92:4467-4471, 1995